US 12,239,638 B2
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
Lori Jean Patterson, San Francisco, CA (US); Robert S. Chao, Santa Clara, CA (US); and Miroslav Rapta, San Carlos, CA (US)
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed by THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US)
Filed on Feb. 28, 2023, as Appl. No. 18/115,436.
Application 14/728,079 is a division of application No. 14/060,846, filed on Oct. 23, 2013, granted, now 9,073,859, issued on Jul. 7, 2015.
Application 14/060,846 is a division of application No. 13/632,588, filed on Oct. 1, 2012, granted, now 8,592,596, issued on Nov. 26, 2013.
Application 13/632,588 is a division of application No. 12/617,838, filed on Nov. 13, 2009, granted, now 8,304,433, issued on Nov. 6, 2012.
Application 18/115,436 is a continuation of application No. 17/248,737, filed on Feb. 5, 2021, granted, now 11,596,624.
Application 17/248,737 is a continuation of application No. 16/744,551, filed on Jan. 16, 2020, granted, now 10,946,006, issued on Mar. 16, 2021.
Application 16/744,551 is a continuation of application No. 16/244,956, filed on Jan. 10, 2019, granted, now 10,576,073, issued on Mar. 3, 2020.
Application 16/244,956 is a continuation of application No. 15/586,531, filed on May 4, 2017, granted, now 10,226,454, issued on Mar. 12, 2019.
Application 15/586,531 is a continuation of application No. 14/728,079, filed on Jun. 2, 2015, abandoned.
Claims priority of provisional application 61/114,541, filed on Nov. 14, 2008.
Prior Publication US 2023/0201181 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4465 C07D 211/22 C07D 211/32